Oxford Biomedica (LON:OXB) Reaches New 52-Week High - What's Next?

Key Points

• Oxford Biomedica's share price reached a new 52-week high of GBX 600 ($8.12), closing at GBX 594.75 ($8.05) with a trading volume of 65,561 shares.
• The company's market capitalization stands at £718.68 million, and it has a consensus rating of "Moderate Buy" with a consensus target price of GBX 540.25.
• Recent insider transactions included the sale of 4,563 shares by Dame Kay Davies and the purchase of 11,389 shares by Heather Preston, indicating activity among company insiders.

Oxford Biomedica plc (LON:OXB - Get Free Report)'s share price hit a new 52-week high during mid-day trading on Wednesday . The stock traded as high as GBX 600 ($8.12) and last traded at GBX 594.75 ($8.05), with a volume of 65561 shares. The stock had previously closed at GBX 593 ($8.02).

Analyst Ratings Changes

Several brokerages have recently commented on OXB. Royal Bank Of Canada upped their price objective on shares of Oxford Biomedica from GBX 800 to GBX 930 and gave the company an "outperform" rating in a research note on Tuesday, August 26th. Peel Hunt reiterated a "buy" rating and issued a GBX 451 price objective on shares of Oxford Biomedica in a research report on Friday, August 1st. Finally, JPMorgan Chase & Co. decreased their target price on Oxford Biomedica from GBX 490 to GBX 400 and set a "neutral" rating for the company in a report on Tuesday, July 15th. Two equities research analysts have rated the stock with a Buy rating and two have issued a Hold rating to the stock. According to MarketBeat.com, Oxford Biomedica has a consensus rating of "Moderate Buy" and a consensus target price of GBX 540.25.

Oxford Biomedica Stock Performance

The company has a market capitalization of £718.68 million, a PE ratio of -1,432.34 and a beta of 1.09. The company has a 50 day moving average of GBX 451.78 and a two-hundred day moving average of GBX 354.38. The company has a debt-to-equity ratio of 166.48, a current ratio of 2.35 and a quick ratio of 1.67.

Insider Transactions at Oxford Biomedica

In related news, insider Dame Kay Davies sold 4,563 shares of the stock in a transaction dated Monday, August 18th. The shares were sold at an average price of GBX 500, for a total transaction of £22,815. Also, insider Heather Preston purchased 11,389 shares of the business's stock in a transaction dated Tuesday, June 17th. The shares were purchased at an average price of GBX 324 per share, for a total transaction of £36,900.36. Insiders own 43.30% of the company's stock.

About Oxford Biomedica

Oxford Biomedica LSE: OXB is a quality and innovation-led cell and gene therapy CDMO with a mission to enable its clients to deliver life changing therapies to patients around the world. One of the original pioneers in cell and gene therapy, the Company has more than 25 years of experience in viral vectors; the driving force behind the majority of gene therapies.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.